Full text is available at the source.
Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study
Shorter-acting diabetes drugs linked to higher risk of acid reflux and related problems in type 2 diabetes patients
AI simplified
Abstract
1,543,351 patients with type 2 diabetes were analyzed for risks associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
- GLP-1 RA exposure is associated with a 15% increased risk of erosive reflux disease (HR 1.15; 95% CI 1.09 to 1.22).
- The increased risk of erosive reflux disease is attributable to short-acting GLP-1 RAs (HR 1.215; 95% CI 1.111 to 1.328).
- Long-acting GLP-1 RAs do not show an increased risk of erosive reflux disease (HR 0.994; 95% CI 0.924 to 1.069).
- Short-acting GLP-1 RAs are also linked to higher risks of oesophageal stricture (HR 1.284; 95% CI 1.135 to 1.453).
- Increased risks are observed for Barrett's without dysplasia (HR 1.372; 95% CI 1.217 to 1.546) and Barrett's with dysplasia (HR 1.505; 95% CI 1.164 to 1.946).
AI simplified